Febraayo 15, 2022, Maamulka Cuntada iyo Dawooyinka ee Mareykanka (FDA) ayaa aqbashay codsiga cusub ee adagrassib (NDA) ee daawaynta bukaanada qaba kansarka sambabada unugyada aan yarayn daawaynta ka hor.Sida uu dhigayo sharciga khidmadaha isticmaalaha daawada laguu qoray, maamulayaasha ayaa go'aansan doona inay codsadaan December 14, 2022.
Markii hore, bishii Juun 2021, US FDA waxay siisay adagrassib horumarka daawaynta aqoonsiga daawaynta bukaanada qaba kansarka sambabada unug yar oo la daweeyay oo sidda isku-beddelka KRAS G12C.
Adagrassib waa ka hortagta afka ee KRAS G12C oo awood leh oo gaar ahaaneed leh.Waxay si aan leexleexad lahayn oo si xushmad leh ugu xidhan tahay KRAS G12C oo waxay ku xidhay xaalad aan firfircoonayn.Waxay haysataa nolol badhkeed dheer si ay u gaadho xannibaad joogto ah oo KRAS ah oo u horseedda hawl-qabad qotodheer oo waarta antitumor.
Magaca guud: adagrassib
Xeer: mrtx849
Ujeedka: KRAS G12C
Markii ugu horeysay ee lagu ansixiyay Maraykanka: lama ogola
Markii ugu horeysay ee lagu ansixiyay Shiinaha: lama ogola
Mwax cayriin ah: (R)-3-HYDROXYMETHYL-PIPERAZINE-1-CARBOXYLIC AACID TERT-BUTYL ESTER (CAS: 278788-66-2)
Gabagabo
Waxaa si fiican loo og yahay in isbeddellada KRAS ay adag tahay in la beegsado oo ay leeyihiin ikhtiyaaro daaweyn xaddidan taariikhda, gaar ahaan KRAS G12C biomarkers waxay la xiriiraan natiijooyinka badbaadada liidata.Markan, dib u eegista FDA ee codsiga cusub ee adagrassib waxay calaamad u tahay horumarka muhiimka ah ee bixinta doorashooyin cusub oo lala beegsaday bukaannada NSCLC ee KRAS G12C.
Isha tixraaca:
https://www.onclive.com
https://ir.mirati.com
Waqtiga boostada: Apr-11-2022